Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

A chirality-dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics.

Wu X, Park M, Sarbassova DA, Ying H, Lee MG, Bhattacharya R, Ellis L, Peterson CB, Hung MC, Lin HK, Bersimbaev RI, Song MS, Sarbassov DD.

Int J Cancer. 2019 Aug 31. doi: 10.1002/ijc.32658. [Epub ahead of print]

PMID:
31472018
2.

Formation of mammalian preribosomes proceeds from intermediate to composed state during ribosome maturation.

Abetov DA, Kiyan VS, Zhylkibayev AA, Sarbassova DA, Alybayev SD, Spooner E, Song MS, Bersimbaev RI, Sarbassov DD.

J Biol Chem. 2019 Jul 12;294(28):10746-10757. doi: 10.1074/jbc.AC119.008378. Epub 2019 May 10.

3.

Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.

Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS.

Breast Cancer Res. 2017 Jun 30;19(1):74. doi: 10.1186/s13058-017-0868-8.

4.

High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.

Zeng Z, Liu W, Tsao T, Qiu Y, Zhao Y, Samudio I, Sarbassov DD, Kornblau SM, Baggerly KA, Kantarjian HM, Konopleva M, Andreeff M.

Haematologica. 2017 Sep;102(9):1537-1548. doi: 10.3324/haematol.2016.162230. Epub 2017 Jun 28.

5.

Rictor regulates cell migration by suppressing RhoGDI2.

Agarwal NK, Chen CH, Cho H, Boulb├Ęs DR, Spooner E, Sarbassov DD.

Oncogene. 2013 May 16;32(20):2521-6. doi: 10.1038/onc.2012.287. Epub 2012 Jul 9.

6.

Integrity of mTORC2 is dependent on the rictor Gly-934 site.

Aimbetov R, Chen CH, Bulgakova O, Abetov D, Bissenbaev AK, Bersimbaev RI, Sarbassov DD.

Oncogene. 2012 Apr 19;31(16):2115-20. doi: 10.1038/onc.2011.404. Epub 2011 Sep 12.

7.

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM.

Mol Cell. 2006 Apr 21;22(2):159-68. Epub 2006 Apr 6.

8.

Growing roles for the mTOR pathway.

Sarbassov DD, Ali SM, Sabatini DM.

Curr Opin Cell Biol. 2005 Dec;17(6):596-603. Epub 2005 Oct 13. Review.

PMID:
16226444
9.

Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex.

Sarbassov DD, Sabatini DM.

J Biol Chem. 2005 Nov 25;280(47):39505-9. Epub 2005 Sep 23.

10.

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM.

Science. 2005 Feb 18;307(5712):1098-101.

11.

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM.

Curr Biol. 2004 Jul 27;14(14):1296-302.

12.

GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR.

Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, Sabatini DM.

Mol Cell. 2003 Apr;11(4):895-904.

13.

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM.

Cell. 2002 Jul 26;110(2):163-75.

PMID:
12150925
15.
16.

Role of insulin-like growth factors and myogenin in the altered program of proliferation and differentiation in the NFB4 mutant muscle cell line.

Sarbassov DD, Stefanova R, Grigoriev VG, Peterson CA.

Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10874-8.

Supplemental Content

Loading ...
Support Center